SG11201908129PA - LIQUID BIOPSY FOR cfRNA - Google Patents

LIQUID BIOPSY FOR cfRNA

Info

Publication number
SG11201908129PA
SG11201908129PA SG11201908129PA SG11201908129PA SG 11201908129P A SG11201908129P A SG 11201908129PA SG 11201908129P A SG11201908129P A SG 11201908129PA SG 11201908129P A SG11201908129P A SG 11201908129PA
Authority
SG
Singapore
Prior art keywords
international
california
boulevard
response
pct
Prior art date
Application number
Other languages
English (en)
Inventor
Kathleen Danenberg
Shahrooz Rabizadeh
Joshua Usher
Yolanda Jaimes
Original Assignee
Nantomics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantomics Llc filed Critical Nantomics Llc
Publication of SG11201908129PA publication Critical patent/SG11201908129PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201908129P 2017-03-17 2018-03-15 LIQUID BIOPSY FOR cfRNA SG11201908129PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762473273P 2017-03-17 2017-03-17
US201762522509P 2017-06-20 2017-06-20
US201762593534P 2017-12-01 2017-12-01
PCT/US2018/022747 WO2018170329A1 (fr) 2017-03-17 2018-03-15 Biopsie liquide d'arnac

Publications (1)

Publication Number Publication Date
SG11201908129PA true SG11201908129PA (en) 2019-10-30

Family

ID=63523347

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908129P SG11201908129PA (en) 2017-03-17 2018-03-15 LIQUID BIOPSY FOR cfRNA

Country Status (10)

Country Link
US (1) US20200102618A1 (fr)
EP (1) EP3596231A1 (fr)
JP (1) JP2020511137A (fr)
KR (1) KR20190129094A (fr)
CN (1) CN110431238A (fr)
AU (1) AU2018234821A1 (fr)
CA (1) CA3056700A1 (fr)
IL (1) IL269402A (fr)
SG (1) SG11201908129PA (fr)
WO (1) WO2018170329A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190139314A (ko) * 2017-05-03 2019-12-17 난토믹스, 엘엘씨 종양 대 매칭된 정상 cfRNA (TUMOR VS. MATCHED NORMAL cfRNA)
AU2018266162A1 (en) * 2017-05-10 2020-01-02 Nantomics, Llc Circulating RNA for detection, prediction, and monitoring of cancer
WO2019035075A1 (fr) 2017-08-17 2019-02-21 NantOmics, LLC. Changements dynamiques dans l'arn libre circulant de tumeurs neurales

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201163A1 (fr) * 2005-07-01 2007-01-11 E. R. Squibb & Sons, L.L.C. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
US8304187B2 (en) * 2009-02-18 2012-11-06 Streck, Inc. Preservation of cell-free RNA in blood samples
WO2013006490A2 (fr) * 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Anticorps se liant spécifiquement à tim3
EP2878678A1 (fr) * 2013-12-02 2015-06-03 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Biomarqueurs d'ARN pour le diagnostic du cancer de la prostate
PE20161344A1 (es) * 2014-01-02 2016-12-23 Memorial Sloan Kettering Cancer Center Determinantes de respuesta del cancer a la inmunoterapia
MA40035A (fr) * 2014-10-14 2016-04-21 Dana Farber Cancer Inst Inc Molécules d'anticorps de pd-l1 et leurs utilisations
CA2965528A1 (fr) * 2014-11-14 2016-05-19 Liquid Genomics, Inc. Utilisation d'arn acellulaire circulant pour le diagnostic et/ou la surveillance du cancer
KR20170138555A (ko) * 2015-04-28 2017-12-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료

Also Published As

Publication number Publication date
EP3596231A1 (fr) 2020-01-22
AU2018234821A1 (en) 2019-09-26
KR20190129094A (ko) 2019-11-19
US20200102618A1 (en) 2020-04-02
CA3056700A1 (fr) 2018-09-20
JP2020511137A (ja) 2020-04-16
IL269402A (en) 2019-11-28
WO2018170329A1 (fr) 2018-09-20
CN110431238A (zh) 2019-11-08

Similar Documents

Publication Publication Date Title
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201909154SA (en) Bispecific antibodies specifically binding to pd1 and lag3
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201909205YA (en) Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
SG11201811405QA (en) Improved differentiation method
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201806150RA (en) Psma and cd3 bispecific t cell engaging antibody constructs
SG11201908088RA (en) Antibodies against pd-l1
SG11201901006RA (en) Systems and methods for enhanced organizational transparency using a credit chain
SG11201907023UA (en) Method of reducing neutropenia
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201803983UA (en) Transformable tagging compositions, methods, and processes incorporating same
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201908847TA (en) Apparatuses, systems and methods for imaging flow cytometry
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201810887UA (en) Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
SG11201908127WA (en) Method for producing multispecific antibodies
SG11201806401YA (en) G protein-coupled receptor (gpcr) modulation by imipridones
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201901991QA (en) Methods of detecting per cell pd-l1 expression and uses thereof
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer